SMTI

Sanara Medtech Inc

Add to Watchlist

Advanced Chart

26.310

-1.15(-4.188%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

28.360

Open

27.770

VWAP

27.11

Vol

51.69K

Mkt Cap

233.84M

Low

26.310

Amount

1.40M

EV/EBITDA(TTM)

Total Shares

8.63M

256.55M

EV/OCF(TTM)

P/S(TTM)

2.45

Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

25.15M

+24.76%

25.78M

+18.93%

29.93M

+13.76%

Estimates Revision

The market is revising Upward the revenue expectations for Sanara MedTech Inc. (SMTI) for FY2025, with the revenue forecasts being adjusted by 2.63% over the past three months. During the same period, the stock price has changed by -8.20%.

Revenue Estimates for FY2025

Revise Upward

+2.63%

In Past 3 Month

Stock Price

Go Down

-8.20%

In Past 3 Month

2 Analyst Rating

86.24% Upside

Wall Street analysts forecast SMTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMTI is 49.00 USD with a low forecast of 45.00 USD and a high forecast of 53.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

86.24% Upside

Current: 26.310

Low

45.00

Averages

49.00

High

53.00

86.24% Upside

Current: 26.310

Low

45.00

Averages

49.00

High

53.00

H.C. Wainwright

Yi Chen

Buy

maintain

$51 -> $53

2025-05-15

Reason

H.C. Wainwright

Yi Chen

Price Target

$51 -> $53

2025-05-15

maintain

Buy

Reason

H.C. Wainwright analyst Yi Chen raised the firm's price target on Sanara MedTech to $53 from $51 and keeps a Buy rating on the shares following the Q1 report. The firm believes Sanara Surgical segment could continue to drive sales growth as the company increases regional sales managers and territories and grows distribution partners.

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

$46

2025-03-26

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

$46

2025-03-26

Reiterates

Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$50 → $51

2025-03-26

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$50 → $51

2025-03-26

Maintains

Strong Buy

Reason

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

$44

2025-01-23

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

$44

2025-01-23

Reiterates

Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$50

2025-01-23

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$50

2025-01-23

Reiterates

Strong Buy

Reason

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

$44

2025-01-22

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

$44

2025-01-22

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Sanara Medtech Inc (SMTI.O) is -18.21, compared to its 5-year average forward P/E of -9.41. For a more detailed relative valuation and DCF analysis to assess Sanara Medtech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.41

Current PE

-18.21

Overvalued PE

65.33

Undervalued PE

-84.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

3.20

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

17.35

Undervalued EV/EBITDA

-10.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.46

Current PS

2.22

Overvalued PS

7.17

Undervalued PS

1.76